Table 2. Checkpoint inhibitors: differences of binding affinity.
| Drug | Target | Antibody type | Affinity/K2 |
|---|---|---|---|
| Nivolumab | PD-1 | Finally human IgG4 | 2.6 nM |
| Pembrolizumab | PD-1 | Humanized IgG4 kappa | 29 pM |
| AMP-224 | PD-L2 | PD-L2 IgG1 Fc fusion | NA |
| Pidilizumab (CT-011) | PD-1 | Humanized IgG1 kappa | 20 nM |
| Atezolizumab | PD-L1 | Engineered IgG1 (no ADCC) | 0.4 nM |
| Durvalumab | PD-L1 | Modified IgG1 (no ADCC) | NA |
| Avelumab | PD-L1 | Humanized IgG1 | NA |
| BMS-936559 | PD-L1 | Humanized IgG4 | NA |
ADCC, antibody dependent cell-mediated cytotoxicity; Ig, immunoglobuline; NA, not available.